| 000 | 01102 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250515113602.0 | ||
| 264 | 0 | _c20080328 | |
| 008 | 200803s 0 0 eng d | ||
| 022 | _a1538-3598 | ||
| 024 | 7 |
_a10.1001/jama.299.12.1474 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPsaty, Bruce M | |
| 245 | 0 | 0 |
_aSurrogate end points and FDA approval: a tale of 2 lipid-altering drugs. _h[electronic resource] |
| 260 |
_bJAMA _cMar 2008 |
||
| 300 |
_a1474-6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAzetidines _xtherapeutic use |
| 650 | 0 | 4 | _aBiomarkers |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aDrug Approval |
| 650 | 0 | 4 | _aEzetimibe |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypolipidemic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aQuinolines _xtherapeutic use |
| 650 | 0 | 4 | _aRisk |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 | _aUnited States Food and Drug Administration |
| 700 | 1 | _aLumley, Thomas | |
| 773 | 0 |
_tJAMA _gvol. 299 _gno. 12 _gp. 1474-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1001/jama.299.12.1474 _zAvailable from publisher's website |
| 999 |
_c17864974 _d17864974 |
||